Barclays raised the firm’s price target on Travere Therapeutics to $14 from $12 and keeps an Overweight rating on the shares. The company is setup well for second half of 2024 updates after the modest Filspari beat in Q2, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics, Inc. (TVTX) Q2 Earnings Cheat Sheet
- Travere Therapeutics to Report Second Quarter 2024 Financial Results
- Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)